These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 9627133)

  • 1. Binding of properdin to solid-phase immune complexes: critical role of the classical activation pathway of complement.
    Junker A; Baatrup G; Svehag SE; Wang P; Holmström E; Sturfelt G; Sjöholm AG
    Scand J Immunol; 1998 May; 47(5):481-6. PubMed ID: 9627133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
    Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
    J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of C1s, C1r and properdin in the initiation of the C3b-dependent feedback mechanism of the complement system.
    Johnson U
    Acta Pathol Microbiol Scand C; 1978 Apr; 86(2):73-8. PubMed ID: 696332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solubilization of immune precipitates by six isolated alternative pathway proteins.
    Fujita T; Takata Y; Tamura N
    J Exp Med; 1981 Dec; 154(6):1743-51. PubMed ID: 6459396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
    Mayes JT; Schreiber RD; Cooper NR
    J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of immune precipitation by purified components of the alternative pathway.
    Naama JK; Holme E; Hamilton E; Whaley K
    Clin Exp Immunol; 1985 Apr; 60(1):169-77. PubMed ID: 3159522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification.
    Jelezarova E; Vogt A; Lutz HU
    Biochem J; 2000 Jul; 349(Pt 1):217-23. PubMed ID: 10861231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
    Densen P; McRill CM; Ross SC
    J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble collectin-12 mediates C3-independent docking of properdin that activates the alternative pathway of complement.
    Zhang J; Song L; Pedersen DV; Li A; Lambris JD; Andersen GR; Mollnes TE; Ma YJ; Garred P
    Elife; 2020 Sep; 9():. PubMed ID: 32909942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae.
    Agarwal S; Ferreira VP; Cortes C; Pangburn MK; Rice PA; Ram S
    J Immunol; 2010 Jul; 185(1):507-16. PubMed ID: 20530262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of activated properdin with complexes of properdin with C3.
    Whiteman LY; Purkall DB; Ruddy S
    J Immunol; 1991 Aug; 147(4):1344-51. PubMed ID: 1869827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of immune complexes to erythrocyte CR1 (CD35): difference in requirement of classical pathway components and indication of alternative pathway-mediated binding in C2-deficiency.
    Klint C; Gullstrand B; Sturfelt G; Truedsson L
    Scand J Immunol; 2000 Jul; 52(1):103-8. PubMed ID: 10886790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of components of the properdin system to cultured human lymphoblastoid cells and B lymphocytes.
    Theofilopoulos AN; Perrin LH
    J Exp Med; 1976 Feb; 143(2):271-89. PubMed ID: 1082488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirements for the solubilization of immune aggregates by complement. The role of the classical pathway.
    Takahashi M; Takahashi S; Brade V; Nussenzweig V
    J Clin Invest; 1978 Aug; 62(2):349-58. PubMed ID: 670397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
    Medicus RG; Götze O; Müller-Eberhard HJ
    J Exp Med; 1976 Oct; 144(4):1076-93. PubMed ID: 978134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
    Pangburn MK; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of activated properdin to untreated erythrocytes: a new function of activated properdin.
    Konno T; Hirai H; Tamura N
    Immunology; 1978 Feb; 34(2):207-15. PubMed ID: 627406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Properdin: initiation of alternative complement pathway.
    Fearon DT; Austen KF
    Proc Natl Acad Sci U S A; 1975 Aug; 72(8):3220-4. PubMed ID: 1059108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.